Sign In
Buy COWN
$38.99
+0 (+0%)
At Close: May 26, 2023
Lockheed Martin CFO to Speak at the TD Cowen 46th Annual Aerospace & Defense Conference
09:00am, Thursday, 06'th Feb 2025
BETHESDA, Md. , Feb. 6, 2025 /PRNewswire/ -- Lockheed Martin (NYSE: LMT) CFO Jay Malave will participate in a fireside chat at the TD Cowen 46th Annual Aerospace & Defense Conference on Thursday, Feb
Red Cat CEO Jeff Thompson to Present at TD Cowen's 46th Annual Aerospace & Defense Conference
02:59pm, Tuesday, 04'th Feb 2025
SAN JUAN, Puerto Rico, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) ("Red Cat") ("Red Cat"), a drone technology company integrating robotic hardware and software for militar
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
04:30pm, Monday, 03'rd Feb 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a firesid
TD Cowen's Bill Katz on Apollo: A significant number of growth drivers ahead into 2025
10:30am, Monday, 23'rd Dec 2024
Bill Katz, TD Cowen senior equity analyst, joins 'Squawk on the Street' to discuss the latest market trends, impact of Apollo Global Management joining the S&P 500, 2025 outlook for asset managers, an
Novo Nordisk price target lowered to $105 from $155 at TD Cowen
03:41pm, Friday, 20'th Dec 2024
TD Cowen lowered the firm's price target on Novo Nordisk to $105 from $155 and keeps a Buy rating on the shares.
Nike is setting a very low bar for its turnaround plan, says TD Cowen's John Kernan
07:49am, Friday, 20'th Dec 2024
John Kernan, TD Cowen managing director and retail analyst, joins 'Squawk Box' to discuss Nike's turnaround plan, the challenges facing new CEO Elliott Hill, and more.
CVS Health has strong position in DOJ case, says TD Cowen
07:05pm, Thursday, 19'th Dec 2024
TD Cowen keeps a Buy rating and $80 price target on CVS. The firm says the DOJ complaint relating to opioid prescriptions is incremental to the 2022 settlement with state and local governments for $5B
Osisko Gold downgraded to Hold from Buy at TD Cowen
05:36am, Monday, 11'th Nov 2024
TD Cowen analyst Derick Ma downgraded Osisko Gold to Hold from Buy with an unchanged price target of C$31. The firm cites valuation for the downgrade following the stock's recent appreciation.
GCM Grosvenor downgraded to Hold from Buy at TD Cowen
05:34am, Monday, 11'th Nov 2024
TD Cowen downgraded GCM Grosvenor to Hold from Buy with a price target of $12.50, down from $13.50.
Upside expected for Amazon as fulfillment efficiency increases margins, says Cowen's Blackledge
11:22am, Friday, 01'st Nov 2024
John Blackledge, senior internet analyst at Cowen, joins CNBC's 'Squawk on the Street' to discuss his buy rating for Amazon, expectations for the stock, and more.
A lot the industry dynamics have shifted in favor of United and Delta: TD Cowen's Tom Fitzgerald
08:41am, Monday, 28'th Oct 2024
Tom Fitzgerald, TD Cowen analyst, joins 'Squawk Box' to discuss news of Boeing's capital raise, impact of Boeing's strike on airlines, tailwinds for airline stocks, and more.
Centrus to Participate in TD Cowen's 2024 Nuclear Fuel & Next Generation Roundtable
06:30am, Monday, 30'th Sep 2024
BETHESDA, Md. , Sept. 30, 2024 /PRNewswire/ -- Centrus Energy Corp. (NYSE American: LEU) today announced that management are scheduled to participate in TD Cowen's 2024 Nuclear Fuel & Next Generati
Ulta Beauty downgraded as TD Cowen cites medium-term challenges
09:18am, Monday, 23'rd Sep 2024
Ulta Beauty Inc. was downgraded by TD Cowen Monday, with the analyst firm citing the increasing cost of competition for the specialty retailer.
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
04:30pm, Thursday, 19'th Sep 2024
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
04:01pm, Thursday, 19'th Sep 2024
SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m.
